Browse > Article

The Effect of PDE4 Inhibitor on LPS-Induced Osteoclastogenesis  

No, A-Long-Sae-Mi (College of Pharmacy, Sookmyung Women's University)
Chen, Ling (College of Pharmacy, Sookmyung Women's University)
Yim, Mi-Jung (College of Pharmacy, Sookmyung Women's University)
Publication Information
YAKHAK HOEJI / v.52, no.1, 2008 , pp. 43-47 More about this Journal
Abstract
To determine the regulatory roles of PDE4 inhibitor on LPS-induced osteoclastogenesis, we investigated the effect of a PDE4 inhibitor on osteoclast formation in the presence of LPS. A specific PDE4 inhibitor, rolipram, increased LPS-induced osteoclast formation in cocultures. To verify that whether rolipram acts indirectly on osteoblasts, we investigated the TRANCE and COX-2 mRNA expression levels in osteoblasts. Treatment of rolipram increased the expression of TRANCE and COX-2 mRNA in osteoblasts stimulated by LPS. On the contrary, rolipram did not augment the number of osteoclasts differentiated from bone marrow cells by LPS. In conclusion, the stimulation of LPS-induced osteoclast formation by the PDE4 inhibitor are attributable to its indirect effect on osteoblasts, not to their direct effect on bone marrow-derived osteoclast precursors.
Keywords
LPS; phosphodiesterase 4 inhibitor; osteoblast; osteoclast;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T. : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597 (1998)
2 Park, H., Young Lee, S., Lee, D. S. and Yim, M. : Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts. Biochem. Biophys. Res. Commun. 354, 178 (2007)
3 Yao, W., Tian, X. Y., Chen, J., Setterberg, R. B., Lundy, M. W., Chmielzwski, P., Froman, C. A. and Jee, W. S. : Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats. J. Musculoskelet Neuronal Interact. 7, 119 (2007)
4 Suda, K., Woo, J. T., Takami, M., Sexton, P. M. and Nagai, K. : Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL. J. Cell Physiol. 190, 101 (2002)
5 Jin, S. L., Lan, L., Zoudilova, M. and Conti, M. : Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J. Immunol. 175, 1523 (2005)
6 Wang, P. L. and Ohura, K. : Porphyromonas gingivalis lipopolysaccharide signaling in gingival fibroblasts-CD14 and Toll-like receptors. Crit. Rev. Oral. Biol. Med. 13, 132 (2002)
7 Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S. 3rd, Frankel, W. N., Lee, S. Y. and Choi, Y. : TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun Nterminal kinase in T cells. J. Biol. Chem. 272, 25190 (1997)
8 Sakuma, Y., Tanaka, K., Suda, M., Komatsu, Y., Yasoda, A., Miura, M., Ozasa, A., Narumiya, S., Sugimoto, Y., Ichikawa, A., Ushikubi, F. and Nakao, K. : Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. Infect Immun. 68, 6819 (2000)
9 Kaji, H., Sugimoto, T., Kanatani, M., Fukase, M., Kumegawa, M. and Chihara, K. : Prostaglandin $E_2$ stimulates osteoclastlike cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J. Bone Miner. Res. 11, 62 (1996)
10 Essayan, D. M. : Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108, 671 (2001)   DOI   ScienceOn
11 Lagente, V., Martin-Chouly, C., Boichot, E., Martins, M. A. and Silva, P. M. : Selective PDE4 inhibitors as potent antiinflammatory drugs for the treatment of airway diseases. Mem. Inst. Oswaldo. Cruz. 100, Suppl 1:131 (2005)
12 Nair, S. P., Meghji, S., Wilson, M., Reddi, K., White, P. and Henderson, B. : Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun. 64, 2371 (1996)
13 Itoh, K., Udagawa, N., Kobayashi, K., Suda, K., Li, X., Takami, M., Okahashi, N., Nishihara, T. and Takahashi, N. : Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J. Immunol. 170, 3688 (2003)
14 Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W. J. : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165 (1998)
15 Suda, K., Udagawa, N., Sato, N., Takami, M., Itoh, K., Woo, J. T., Takahashi, N. and Nagai, K. : Suppression of osteoprotegerin expression by prostaglandin $E_2$ is crucially involved in lipopolysaccharide-induced osteoclast formation. J. Immunol. 172, 2504 (2004)
16 Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J. and Suda, T. : Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600 (1988)
17 Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T. and Martin, T. J. : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345 (1999)
18 Bender, A. T. and Beavo, J. A. : Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488 (2006)
19 Coon, D., Gulati, A., Cowan, C. and He, J. : The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption. J. Endod. 33, 432 (2007)